29-SEP-2025 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424 8mg 67 5 0 0 0 0 0 02/08/2021 81 41
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   14 7 5 4 3 0      
            24 7 5 4 3 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 54 14 5 2 1 1 03/02/2021 261 92
        2 Early V-O   103 28 13 3 2 0      
            157 42 18 5 3 1      
 
  MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 1 Y 1 ASTX727 + Venetoclax + Enasidenib (Safety Run-in) 102 6 6 6 4 3 2 05/16/2025 187 51
            6 6 6 4 3 2      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 1 Daunorubicin + Cytarabine 335 10 10 7 6 2 0 09/25/2024 284 98
        2 Venetoclax + Daunorubicin + Cytarabine   8 8 5 3 1 1      
        3 Venetoclax + Azacitidine   8 8 6 4 1 0      
        4 (Daunorubicin + Cytarabine) Liposome   9 8 6 4 2 0      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   8 8 6 3 2 1      
            43 42 30 20 8 2      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   710 664 310 162 52 9 06/18/2024 332 129
            710 664 310 162 52 9      
 
    2 Y 2 Re-screening   59 59 21 12 5 1 06/18/2024    
            59 59 21 12 5 1      
 
    3 Y 3 Re-screening   12 12 9 4 2 0 06/18/2024    
            12 12 9 4 2 0      
 
    4 Y 4 Re-screening   1 1 0 0 0 0 06/18/2024    
            1 1 0 0 0 0      
 
Yes EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   6 1 0 0 0 0 02/24/2023 99 32
            6 1 0 0 0 0      
 
    1 E Total Registrations   3 0 0 0 0 0 02/24/2023    
            3 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 263 86
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 0 0 0 0 0 08/13/2020 145 49
            11 0 0 0 0 0      
 
    1 E Total Registrations   5 0 0 0 0 0 08/13/2020    
            5 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   59 14 8 4 1 0 02/19/2021 168 55
            59 14 8 4 1 0      
 
    1 E Total Registrations   48 11 6 3 0 0 02/19/2021    
            48 11 6 3 0 0      
 
    2 E Total Registrations   42 9 6 3 0 0 02/19/2021    
            42 9 6 3 0 0      
 
  MM1OAEA02-MyeloMATCH: AML, New Dx, Ven+HMA 1 E Total Registrations   9 9 6 5 1 0 12/02/2024 277 95
            9 9 6 5 1 0      
 
  MM1YACTG01-MyeloMATCH: AML, New/Young/Int, Ven+Chemo 1 E Total Registrations   5 5 3 2 1 0 10/14/2024 240 82
            5 5 3 2 1 0      
 

29-SEP-2025 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone 1 Initial Registration 15-May-25    
  2 Post-Remission 15-May-25    
  3 Maintenance 15-May-25    
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 168 55